| Dr Susan Keiko Nakamura, MD | |
|
3350 La Jolla Village Dr, Pmrs 117, San Diego, CA 92161-0002 | |
| (858) 642-1147 | |
| Not Available |
| Full Name | Dr Susan Keiko Nakamura |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 3350 La Jolla Village Dr, San Diego, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033129960 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | G76337 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Susan Keiko Nakamura, MD 3350 La Jolla Village Dr, Pmrs 117, San Diego, CA 92161-0002 Ph: (858) 642-1147 | Dr Susan Keiko Nakamura, MD 3350 La Jolla Village Dr, Pmrs 117, San Diego, CA 92161-0002 Ph: (858) 642-1147 |
News Archive
Akorbi, one of the health insurance industry's largest suppliers of translation and interpretation services, announced an aggressive growth strategy in early 2012 that included the addition of multilingual and technology consulting staffing services.
For the first time in Florida, patients with glaucoma have a new treatment option known as the Trabectome. The minimally invasive procedure, which is available at Mayo Clinic and takes about 20 minutes, is designed to decrease pressure within the eye and stabilize the vision.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).
A study recently published in the journal Circulation looks at temporal trends in the burden of comorbidities and associated risk of mortality among patients with heart failure (HF) with preserved ejection fraction (HFpEF), in which the left ventricle of the heart is not able to relax enough to fill properly with blood, and HF with reduced ejection fraction (HFrEF), in which the left ventricle is not able contract enough to pump out as much blood.
› Verified 5 days ago
Dr. Rogelio Hernandez Jr., DPT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1764 San Diego Ave, Suite 100, San Diego, CA 92110 Phone: 619-291-1959 | |
James Donald Fontaine, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 4765 Carmel Mountain Rd, 207b, San Diego, CA 92130 Phone: 858-876-1300 | |
David Ryan Bakal, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 | |
Jake Fellow, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 11848 Bernardo Plaza Ct Ste 100, San Diego, CA 92128 Phone: 858-217-2496 | |
Dr. Blake R Thompson, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 9040 Friars Rd, Suite 400, San Diego, CA 92108 Phone: 619-284-6377 Fax: 619-528-2841 | |
Mr. Rajiv D Reddy, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 619-543-5754 |